Protalix BioTherapeutics, Inc. Quarterly Deferred Income Tax Assets, Net in USD from Q4 2022 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
Summary
Protalix BioTherapeutics, Inc. quarterly Deferred Income Tax Assets, Net history and growth rate from Q4 2022 to Q2 2024.
  • Protalix BioTherapeutics, Inc. Deferred Income Tax Assets, Net for the quarter ending June 30, 2024 was $3.3M, a 5.4% increase year-over-year.
Deferred Income Tax Assets, Net, Quarterly (USD)
Deferred Income Tax Assets, Net, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $3.3M +$169K +5.4% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $3.23M Mar 31, 2024 10-Q 2024-05-10
Q4 2023 $3.09M +$3.09M Dec 31, 2023 10-Q 2024-08-14
Q3 2023 $3.09M Sep 30, 2023 10-Q 2023-11-06
Q2 2023 $3.13M Jun 30, 2023 10-Q 2023-08-07
Q4 2022 $0 Dec 31, 2022 10-K 2024-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.